Blood Disorders Day

Venous Thromboembolism

CancerCare Manitoba
ActionCancerManitoba

Intial Management of VTE

***Dabigatran:** Avoid if CrCl <30 ml/min
Rivaroxaban/Apixaban: Caution for CrCL 15-30 ml/min; Avoid use if CrCl <15ml/min

Venous thrombosis
(Incidental OR symptomatic; DVT OR PE)

Proximal clot

Distal clot → Subsegmental PE (SSPE) **or** Distal DVT

Safe to treat as outpatient?

NO → Hospitalization

YES

Safe to Anticoagulate?

NO/UNCLEAR → **Page Hematologist On-call**
Absolute contraindication to anticoagulation:
» Uncontrolled bleeding
» Thrombocytopenia (platelet <30 x 10e9/L)

YES

Anticoagulation IF
» Very symptomatic
» Multiple SSPE
» Ongoing risk for thrombus extension (active malignancy, immobilization, etc)

Observation with serial imaging IF
» Isolated SSPE AND bilateral leg US is negative for DVT
» Distal DVT needs q5-7days leg US for 2 weeks (or until symptom resolution)

Initial choice of anticoagulation
(for the first 3 months)

Warfarin (with UFH/LMWH for at least 5 days, target INR 2-3) IF
» GFR <30 mL/min
» Financial concern
» Patient is at low bleeding risk
» Patient has stable diet
» Patient has no major drug interaction
» Patient is reliable for INR monitoring

Direct Oral Anticoagulant (DOAC)
» CrCl <15-30ml/min *
» Weight is between 40-120 kg
» Good oral intake
» Not on dual P-glycoprotein and CYP3A4 inhibitors
» Avoid use in patients with upper GI cancer due to bleeding risk
» Avoid use if dose adjustment for thrombocytopenia is anticipated

Low Molecular Weigh Heparin (LMWH) IF
» GFR>30mL/min
» Advanced cancer (especially upper GI cancer)
» Poor oral intake
» Active chemotherapy with anticipated need for dose adjustment for thrombocytopenia
  » Platelet >50 – 100% dose
  » Platelet 30-50– 50% dose
  » Platelet 20-30– Prophylaxis dose
  » Platelet <20 – Hold

US = Ultrasound
DOAC = Direct oral anticoagulant
VTE = venous thromboembolism
UFH = unfractionated heparin
LMWH = low molecular weight heparin

© Blood Disorder Day
Pathways are subject to clinical judgement and actual practice patterns may not always follow the proposed steps in this pathway.

University of Manitoba

Blood Disorders Day

Venous Thromboembolism

CancerCare Manitoba
ActionCancerManitoba



OCP = Oral contraceptive pill
HRT = Hormone replacement therapy
VTE = venous thromboembolism

© Blood Disorder Day

Pathways are subject to clinical judgement and actual practice patterns may not always follow the proposed steps in this pathway.

University of Manitoba